• van LeeuwenFijs W BFWBInterventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands f.w.b.van_leeuwen@lumc.nl.Department of Urology, Netherlands Cancer Institute, Antoni van Leeuwenhoek Hos, Margret Schottelius, Oscar R Brouwer, Sergi Vidal-Sicart, Samuel Achilefu, Joachim Klode, Hans-Jurgen Wester, and Tessa Buckle.
• Interventional Molecular Imaging Laboratory, Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands f.w.b.van_leeuwen@lumc.nl.
• J. Nucl. Med. 2020 Jan 1; 61 (1): 13-19.

AbstractBy contributing to noninvasive molecular imaging and radioguided surgery, nuclear medicine has been instrumental in the realization of precision medicine. During the last decade, it has also become apparent that nuclear medicine (e.g., in the form of bimodal/hybrid tracers) can help to empower fluorescence-guided surgery. More specifically, when using hybrid tracers, lesions can be noninvasively identified and localized with a high sensitivity and precision (guided by the radioisotope) and ultimately resected under real-time optical guidance (fluorescent dye). This topical review discusses early clinical successes, preclinical directions, and key aspects that could have an impact on the future of this field.© 2020 by the Society of Nuclear Medicine and Molecular Imaging.

36 keywords...

hide…